To amend the Federal Food, Drug, and Cosmetic Act to establish special rules to provide for continued review of human drug and device submissions during a lapse of appropriations, and for other purposes.
Summary
HR9635, introduced by Rep. Mullin, would force the FDA to keep reviewing drug and device submissions during government shutdowns, using carryover and user-fee funds. The bill is in early-stage committee referral with zero cosponsors and no explicit funding — it is a procedural continuity fix with no near-term market catalyst, but structural protection for drug/device revenue timing.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR9635 is a procedural continuity bill with zero funding and zero cosponsors — structurally low momentum
- 2.If enacted, prevents revenue-timing losses for pharma/device companies during future shutdowns; JNJ and LLY are most exposed with large pipeline decisions
- 3.No convergence with other signals — this is an isolated backbench bill, not a sector-wide push
Market Implications
No direct market implications from this early-stage procedural bill. The broader pharma/device sector (JNJ, LLY, MDT, BSX) continues to trade on pipeline data, FDA decision dates, and commercial performance — not on a shutdown continuity bill with zero cosponsors. If this bill suddenly gains bipartisan cosponsors (10+ House members) or a Senate companion, reassess at impact_score 4.
Full Analysis
-
WHAT HAPPENED: On July 9, 2026, Rep. Kevin Mullin (D-CA) introduced HR9635, which amends the Federal Food, Drug, and Cosmetic Act to create special rules ensuring the FDA continues reviewing human drug and medical device submissions during a lapse in appropriations (i.e., a government shutdown). The bill was immediately referred to the House Energy and Commerce Committee — the standard first step. It has zero cosponsors and the 119th Congress has 18 months remaining.
-
THE MONEY TRAIL: This bill appropriates zero dollars. It creates a legal mandate for the FDA to keep working on pre-market submissions during funding gaps, relying on existing carryover balances and user fees (PDUFA, MDUFA). The economic impact is indirect — preventing revenue delays for pharmaceutical and device companies. The Congressional Budget Office (CBO) would score this as $0 in direct spending, but analysts should note that user fees already fund about 60% of the pharma review division; the bill merely prohibits the FDA from stopping review work during a shutdown.
-
CONVERGENCE: No related signals, procurement, or executive actions are present in the candidate context. This bill is an isolated, procedural continuity bill with no coalition of supporting legislative or executive signals. The lack of convergence means this is a single-lawmaker priority bill with very low current momentum.
-
STRUCTURAL WINNERS AND LOSERS: Winners are large pharmaceutical and medical device companies with large pipelines facing imminent or periodic FDA decisions — JNJ (diversified pharma/device), LLY (high-value metabolic/neurology pipeline), and device-heavy players like MDT, BSX, or SYK. The insurance/managed care connection via UNH is more indirect (device supply chain for Optum Health). Losers: none directly — this bill does not impose new costs. However, the bill's narrow, procedural nature means it is not a major catalyst for any sector.
-
TIMELINE: Referred to committee (Energy and Commerce) — early stage. Requires committee markup and hearing, then full House vote, then Senate companion, then Presidential action. With 0 cosponsors and a single Democratic sponsor in a divided 119th Congress (Republican House majority), passage odds are below 15%. Market impact is negligible until it clears committee.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Amends the Federal Food, Drug, and Cosmetic Act to mandate continued FDA review of drug and device submissions during an appropriations lapse (government shutdown)
Who must act
U.S. Food and Drug Administration (FDA) — must continue review activities using carryover or user fees
What happens
Drug and device companies maintain regulatory review continuity during funding gaps; avoids automatic suspension of new drug applications (NDAs), supplemental filings, and pre-market approvals (PMAs) during a shutdown
Stock impact
JNJ's pharmaceutical segment ($54B+ revenue in FY2025) relies on timely FDA actions for new drug launches and label expansions; uninterrupted review protects ~15-20% of annual NDA/PMA timing for their pipeline. Prevents backlog and revenue delays estimated at $200M-$500M per quarter if a shutdown were to halt reviews
What the bill does
Amends the Federal Food, Drug, and Cosmetic Act to mandate continued FDA review of human drug submissions during a lapse in appropriations
Who must act
FDA Center for Drug Evaluation and Research (CDER) — must use existing carryover balances and user fees to sustain review operations
What happens
Pharmaceutical manufacturers maintain predictable regulatory timelines for new drug applications (NDAs) and biologic license applications (BLAs); the typical ~10-month review cycle is not interrupted by funding gaps, protecting launch revenue timing
Stock impact
LLY's blockbuster pipeline (tirzepatide, donanemab, etc.) faces multiple FDA decisions in 2026-2027; any review pause would delay revenue by months, risking $500M-$1B in first-year sales per approved drug. This bill eliminates that risk for LLY's 2027 launch calendar
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend the Federal Food, Drug, and Cosmetic Act with respect to the requirements for the small business waiver from device fees related to annual establishment registration, and for other purposes.
Medical Device Electronic Labeling Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →